The present disclosure provides processes for the preparation of a compound of formula I:

##STR00001##

which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.

Provided is a method of making ethylenediaminetetraacetic acid (EDTA) comprising the steps: (a) providing a reaction mixture (a) comprising ethylenediamine (EDA) and glycolonitrile (GN), wherein reaction mixture (a) comprises 0% to 0.1% by weight, based on the weight of reaction mixture (a), of any base having pKa of the conjugate acid (PKaH) of 13 or higher; (b) causing or allowing reaction mixture (a) to react to form a dinitrile (DN) compound; (c) bringing the DN into contact with aqueous solution of a base having pKaH of 11 or higher, and causing or allowing the resulting mixture to react to form a diacid compound (DA); (d) causing or allowing the DA to react, either sequentially or simultaneously, with additional GN to form products (Pd); (e) causing or allowing products (Pd) to react with a base having pKaH of 11 or higher, to form EDTA. Also provided is a composition comprising a diacid/dinitrile compound (DADN) wherein each R has the structure: ##STR00001##

Provided is a method of making ethylenediaminetetraacetic acid (EDTA) comprising the steps: (a) providing a reaction mixture (a) comprising ethylenediamine (EDA) and glycolonitrile (GN), wherein reaction mixture (a) comprises 0% to 0.1% by weight, based on the weight of reaction mixture (a), of any base having pKa of the conjugate acid (PKaH) of 13 or higher; (b) causing or allowing reaction mixture (a) to react to form a dinitrile (DN) compound; (c) bringing the DN into contact with aqueous solution of a base having pKaH of 11 or higher, and causing or allowing the resulting mixture to react to form a diacid compound (DA); (d) causing or allowing the DA to react, either sequentially or simultaneously, with additional GN to form products (Pd); (e) causing or allowing products (Pd) to react with a base having pKaH of 11 or higher, to form EDTA. Also provided is a composition comprising a diacid/dinitrile compound (DADN) wherein each R has the structure: ##STR00001##

The present invention provides arylalkylamine compounds as calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention. (Formula I)

##STR00001##

The present invention provides arylalkylamine compounds as calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention. (Formula I)

##STR00001##

The present invention provides a process for the preparation of 4-dimethylaminocrotonic acid of Formula (II) or its salts, which is used as an intermediate for the preparation of afatinib or its salts.

##STR00001##

The present invention provides a process for the preparation of 4-dimethylaminocrotonic acid of Formula (II) or its salts, which is used as an intermediate for the preparation of afatinib or its salts.

##STR00001##

The latex polymer compositions of the present invention exhibit latent crosslinking properties. Latent crosslinking in the polymers takes advantage of the fast interaction between the anionic latex charge and the cationic charge associated with polyfunctional amine crosslinkers. Once the latex is coated onto a substrate, the volatile base evaporates and the groups react to form a crosslinked coating with improved wash-off properties.

The present invention provides arylalkylamine compounds as calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention. (Formula I) ##STR00001##

The present invention provides arylalkylamine compounds as calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention. (Formula I) ##STR00001##